stock market

Showing 7 posts of 7 posts found.

novartis_outside_1

Novartis exec sold off shares before Zolgensma data scandal was revealed

August 19, 2019
Sales and Marketing AveXis, Novartis, Shares, Zolgensma, pharma, stock market

An unnamed Novartis executive sold 925,400 Swiss francs (£778,665) worth of shares in the firm just weeks before the FDA …

stock-exchange-911613_1920

Pharma stocks soar after US midterm elections

November 8, 2018
Business Services, Manufacturing and Production Shares, Stock, Trump, biotech, pharma, stock market

Despite the threat of a bipartisan pricing plan, pharma stocks have soared after the announcement of the results of the …

Realm Therapeutics shares halved after failure of Phase 2 study

August 15, 2018
Research and Development London, Shares, atopic dermatitis, phase 2, stock market

Shares in the London-listed Realm Therapeutics plummeted on Monday after the company reported that a Phase II study of the …

stocks2

Immunomedics’ chief financial officer resigns, shares fall

June 22, 2016
Research and Development, Sales and Marketing Immunomedics, Shares, cfo, stock market

Shares in Immunomedics (Nasdaq: IMMU) fell as much as 11% after the company said its chief financial officer Peter Pfreundschuh …

stocks1

Weekly Movers: Relypsa, Titan Pharma, Allergan…

June 6, 2016
Research and Development, Sales and Marketing Stock, drug trial, research, stock market

The prestigious ASCO meet is underway and results of new drug trials will be a key stock mover over the …

Illumina shares plunge as it cuts Q1 outlook

April 20, 2016
Research and Development, Sales and Marketing Financial, Illumina, Share price, Shares, outlook, revenue, stock market

Shares in Illumina (Nasdaq: ILMN) plunged after the company cut its revenue estimates for the first quarter based on low …

stocks1

Weekly Movers: Valeant, Depomed, Intercept Pharma, Insys Therapeutics and more…

April 18, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Depomed, Intercept Pharma, Relypsa, Share price, Stock Movement, Valeant, stock market

Troubles don’t seem to go away for Canada-based Valeant Pharma (NYSE: VRX) with news of a probable sale doing the …

Latest content